Don’t miss – Page 14 – Endpoints News

SUBSCRIBE

They got bounced out of Alexion. Now David Hallal and Vikas Sinha are back with $150M and a focus on cell and gene therapies

5 months ago

PhI may still be a killing field of failure but PhIII success rates have surged, signaling tectonic shifts in biopharma R&D

5 months ago

Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients

5 months ago

Takeda inks a pair of sales to Novartis and J&J for up to $5.7B, handing over 485 staffers

5 months ago

Tillman Gerngross isn't out to impress you with biobucks, but here are 3 partner deals that should

5 months ago

Pfizer buys a rare disease biotech for $340M-plus, putting them on a path to compete with BioMarin

5 months ago

$250M AstraZeneca spinoff preps leap into 3-way battle with titans for a rare disease market that spans the globe

5 months ago

Top MedImmune research exec joins the team now running Immunocore in wake of an R&D restructuring at AstraZeneca

5 months ago

Hit by setbacks, Lundbeck's Deborah Dunsire inks a $400M cannabinoid buyout, adding a discovery site

5 months ago

Pioneering mRNA CEO Stéphane Bancel bags an eye-popping $58M compensation deal in wake of record IPO

5 months ago

The (corrected) list of the world's top 20 pharma companies

5 months ago

Did a disaster crush your stock in 2018? These biotechs were happy to come up with some rich compensation deals for the CEO anyway

5 months ago

Dan O’Day’s to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start buying stuff

5 months ago

Terry Rosen is looking to leave the thundering herd and blaze a new trail in PD-1 R&D

5 months ago

Why did GSK kill two vaccine R&D programs? CEO Emma Walmsley is glad you asked

5 months ago

'Sophisticated' cyberthieves hacked into Charles River Labs and made off with clients’ drug data

5 months ago

Share price blitzed, analysts in an uproar after lead PhIII drug implodes — and Biogen unveils a $2.5M raise for the CEO

5 months ago

Suffering a series of setbacks, Eli Lilly's oncology group quietly executes 2 of its top mid-stage drugs

5 months ago

Analyst pens a barbed note to Biogen: Shed caution, dump Alzheimer’s and retool at the top — go bold

5 months ago

Fired for code of conduct violations, Ian Smith still grabbed a multimillion-dollar stock package at Vertex — but the cash bonus was axed

5 months ago

Three biotechs reveal some secrets about themselves as they gun for $271M-plus in IPOs

5 months ago

‘Something needs to change’: An Allergan analyst spells out why next week’s vote could still spark a major revamp

5 months ago

Top 20 players: Everybody loves an orphan — especially when they come with blockbuster sales and a long run of exclusivity

5 months ago

Whale watching: What a decade of change at Big Pharma taught us about corporate phenotypes

5 months ago

First page Previous page 11 12 131415 16 17 Next page Last page